Apyx Medical Corp (APYX)
Health Care · medical devices / aesthetics · NASDAQ
Apyx Medical provides advanced helium plasma-based surgical technology for cosmetic body contouring and hospital-based electrosurgical procedures.
What Apyx Medical Corp does
Apyx Medical is a surgical aesthetics company that designs and markets innovative plasma and electrosurgical devices for cosmetic and hospital surgical markets. The company's core products include Renuvion (helium plasma technology for tissue contraction), J-Plasma (hospital surgical platform), and AYON (an FDA-cleared body contouring system launched commercially in 2025 that integrates fat removal, tissue contraction, and electrosurgical capabilities). The company also generates revenue through OEM agreements leveraging its expertise in unique waveforms with other medical device manufacturers.
Themes: surgical aesthetics, body contouring, electrosurgery, helium plasma technology, medical device manufacturing
Fundamentals
- Price$3.05 as of 2026-08-26 close
- Market cap$128M as of 2026-08-26
- 1-year return+46.6% 2025-08-26 close $2.08 → 2026-08-26 close $3.05
- P/En/a negative earnings
- Net margin-16.4% as of 2026-08-27
- Gross margin+63.1% as of 2026-08-27
- ROE-90.6% as of 2026-08-27
- Debt / equity2.74 as of 2026-08-27
- Revenue growth (YoY)+18.2% as of 2026-08-27
- Revenue CAGR (3y)+5.9% SEC XBRL
- Beta1.49 as of 2026-08-27
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How APYX compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-27
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-27
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-27
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-27
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How Apyx Medical Corp looks technically
Apyx Medical Corp (APYX) is trading 20.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 295 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 34, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 11 trading days ago. It is 38.9% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 20.3% below its 200-day average, the long-term trend line — a long-term downtrend | -20.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.91 | $3.91 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.83 | $3.83 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 3.7. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 295 trading days ago — a "golden cross", a bullish long-term signal | 295 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend) | 21.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 34, neither overbought (above 70) nor oversold (below 30) | 33.8 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($2.89 to $4.25) — its "stochastic" reading is 12 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 11.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $4.99 | $4.99 |
|---|---|---|
| From the 52-week high | it is 38.9% below its 52-week high (its highest price of the past year) | -38.9% |
| Above the 52-week low | it is 79.4% above its 52-week low (its lowest price of the past year) | +79.4% |
| Below the 52-week high | it is 38.9% below its highest point of the past year | 38.9% |
| Since a 20-day breakout | it made a new 20-day low about 11 trading days ago | 11 sessions |
| Since a 55-day breakout | it made a new 55-day low about 11 trading days ago | 11 sessions |
| All-time high | its highest closing price on record is $17.49 (set on 2021-11-22) | $17.49 |
| Given back of the 52-week move | over the past year its closes ranged ($1.90 to $4.77), and it has given back a bit over half of its rise from last year’s low — 60% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.90 to $3.00. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 59.9% |
| From the all-time high | it is 82.6% below its all-time high | -82.6% |
| Nearest price level | it is trading 9.9% below a resistance level at $3.35 — a price it turned at three times since 2025-12-29, most recently on 2026-03-20. Since 2024-08-26 it has 8 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +9.9% |
| All-time low | its lowest closing price on record is $0.7554 (set on 2025-04-04) | $0.7554 |
| Above the all-time low | it is 303.8% above its all-time low | +303.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2587 between its high and its low — about 8.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2587 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.44 and $4.49 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.44 – $3.46 – $4.49 |
| Typical daily range (% of price) | its price moves about 8.5% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.5% |
| Stretch from the 200-day average | it is trading 3.0 daily ranges below its 200-day average price (20.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.0 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.15× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bullish engulfing | 9 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 9 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-26 0.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.3% |
|---|---|---|
| Open gap | it gapped 3.5% below the previous close 12 sessions ago and has not traded back through the level it left behind at 4.05 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -3.5% |
| Gap filled | a 2.3% gap up opened on 2026-07-13 has been "filled" 32 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 32 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 25.9 percentage points (the stock lost 22.2% while the market gained 3.7%) | -25.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 27.5 percentage points (the stock lost 25.4% while the market gained 2.1%) | -27.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 24.0 percentage points (the stock lost 12.9% while the market gained 11.1%) | -24.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 27.9 percentage points (the stock gained 46.6% while the market gained 18.7%) | +27.9% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 21% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-21 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 15.7% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -21.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 20% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $3.82 — a volume-weighted average of daily closes over 160 sessions, not a true tick-by-tick VWAP. | -20.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 7% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $3.29 — a volume-weighted average of daily closes over 15 sessions, not a true tick-by-tick VWAP. | -7.3% |
Price levels it has turned at before
APYX last closed at $3.05 on 2026-08-26. Since 2024-08-26 it has turned at 8 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.35 | Resistance | 9.9% above the last close | turned there three times · 2025-12-29 to 2026-03-20 |
| $2.71 | Support | 11.0% below the last close | turned there twice · 2025-07-07 to 2025-07-28 |
| $3.73 | Resistance | 22.3% above the last close | turned there three times · 2026-05-21 to 2026-07-29 |
| $4.18 | Resistance | 37.0% above the last close | turned there twice · 2026-03-24 to 2026-04-17 |
| $1.81 | Support | 40.6% below the last close | turned there four times · 2024-12-24 to 2025-09-03 |
| $1.76 | Support | 42.1% below the last close | turned there twice · 2025-05-13 to 2025-05-28 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $3.70.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $3.25 and $3.65 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $2.89.
This reading has stood for 6 trading days, since 2026-08-19.
Read from daily closes as of 2026-08-26.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · lagging the market · Most volatile (6%+ typical daily range) · At the bottom of its 14-day range (stochastic below 20) · Near the golden pocket (has given back about two thirds of its 52-week move) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-26. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$6.60 range $6.00 – $8.00; median $6.00
Analyst estimates, as of 2026-08-25. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for APYX
- Consensus EPS estimate-$0.096 next reporting period, as of 2026-08-25
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Recurring net losses and history of negative cash flows from operations","Potential need for additional debt or equity financing to sustain operations, which could lead to shareholder dilution or restrictive debt covenants","Dependence on the success and market adoption of the recently launched AYON system"]
What changed in the latest 10-Q
AI-assisted comparison of APYX's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references audited consolidated financial statements for year ended December 31, 2025 (vs. December 31, 2024 in older filing)
- Newer filing adds specific handpiece unit sales data for three months ended March 31, 2026 (26,000 units) and 2025 (19,000 units)
- Newer filing adds expanded discussion of GLP-1 market evolution, including approvals expanding indications, oral versions, competition, pricing pressure, and shift to volume-focused model
- Newer filing adds statement that Renuvion is 'the only FDA-approved device for the treatment of this issue post liposuction' (with hyphen in 'FDA-approved')
- Newer filing adds section on 'Inflation' discussing global supply chain instability, tariffs, mitigation initiatives, and impact on raw materials, freight, and labor costs
- Newer filing states AYON label expansion 510(k) clearance is anticipated in 'the second quarter of 2026'
- Removed:
- Older filing contains nine-month handpiece unit sales data for period ended September 30, 2025 (63,000 units) and 2024 (64,000 units) - removed in newer filing
- Older filing notes 'overall lower number of liposuction procedures and commercial focus on the launch of AYON' as reason for unit sales - removed in newer filing
- Older filing contains GLP-1 statement 'Studies have shown patients taking GLP-1's have experienced a loss of body weight. Currently, three GLP-1's are cleared by the FDA for weight loss, but we anticipate a number of additional drug candidates will be cleared, as well as oral versions of these medications.' - replaced with expanded discussion in newer filing
- Older filing states Renuvion is 'the only FDA approved device for the treatment of this issue post liposuction' (without hyphen) - replaced in newer filing
- Older filing contains detailed 'Recent Activities' section describing May 13, 2025 AYON 510(k) clearance announcement, soft launch, September 2025 commercial launch, and clearance scope - removed in newer filing
- Older filing contains November 2024 cost-saving restructuring details including 25% workforce reduction, $4.3 million annualized savings, bonus elimination, board reduction, and board compensation reduction - removed in newer filing
- Older filing contains statement about 2025 cost savings goals and target of operating expenses below $40 million in 2025 - removed in newer filing
- Older filing begins discussion of tariff monitoring - removed/incomplete in newer filing
- Reworded:
- Older filing: 'Recent Activities' section header; Newer filing: reorganized with 'Recent Activities' content moved and 'Inflation' section added
- Older filing describes GLP-1 market in general terms; Newer filing expands with detailed discussion of market evolution from 'niche, high priced injectable drug segment' to 'broad competitive and increasingly accessible metabolic health platform'
- Older filing: 'loss of body weight'; Newer filing: 'significant loss of body weight'
- Older filing references restructuring actions from November 2024; Newer filing omits all restructuring content
- Notes:
- The newer filing appears truncated at the end with incomplete text about segments and asset information, making full comparison of remaining MD&A sections not possible
- Comparison is between Q2 2026 10-Q (filed May 2026, covering three months ended March 31, 2026) and Q3 2025 10-Q (filed November 2025, covering nine months ended September 30, 2025), which are different reporting periods
- The removal of restructuring details and prior period cost-saving initiatives may reflect transition to newer reporting period rather than substantive change
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for APYX — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding APYX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 1,058,147
- Reported value $3,904,563
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 3 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
APYX had 267,145 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
APYX had 0.63% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.69 days to cover at the same settlement.
- Reported short interest (shares) 267,145
- Short interest (% of shares outstanding) 0.63%
- Prior settlement (shares) 251,668
- Reported change 6.15%
- Days to cover (reported) 4.69
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Candela Medical
- Synergon
- Cutera
- Lumenis
- Cynosure
- Surgical aesthetics devices
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Frequently asked questions
What does Apyx Medical Corp (APYX) do?
Apyx Medical is a surgical aesthetics company that designs and markets innovative plasma and electrosurgical devices for cosmetic and hospital surgical markets. The company's core products include Renuvion (helium plasma technology for tissue contraction), J-Plasma (hospital surgical platform), and AYON (an FDA-cleared body contouring system launched commercially in 2025 that integrates fat removal, tissue contraction, and electrosurgical capabilities).
What sector is Apyx Medical Corp (APYX) in?
Apyx Medical Corp (APYX) is classified in the Health Care sector. Its industry is medical devices / aesthetics. It trades on NASDAQ.
Who are Apyx Medical Corp's (APYX) competitors?
Notable peers of Apyx Medical Corp (APYX) include Candela Medical, Synergon, Cutera, Lumenis and Cynosure. This peer set is informational only — not financial advice.
Is Apyx Medical Corp (APYX) overbought or oversold right now?
Apyx Medical Corp (APYX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 34, in the neutral middle (as of 2026-08-26). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on APYX come from?
Fundamentals and prices come from market data, as of 2026-08-27; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-27. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-26.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.